The MAF of each CDH1 variant detected here in leukocyte or tumor DNA was at least four times higher, moreover, all but one variant was significantly more frequent in our glioma families or ODs, WHO grade II/III compared to gnomAD v2.1.1 controls (http://gnomad.broadinstitute.org/) (Suppl. This evidence concerns the gene CDH1 and central nervous system cancer.